Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, has released two video presentations related to the ONCOS-102 mesothelioma 24-month data.
Source: yahoo.com